Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives.

ABSTRACT: In the last decade, antibody-drug conjugates (ADCs), normally formed by a humanized antibody and a small drug via a chemical cleavable or non-cleavable linker, have emerged as a potential treatment strategy in cancer disease. They allow to get a selective delivery of the chemotherapeutic agents at the tumor level, and, consequently, to improve the antitumor efficacy and, especially to decrease chemotherapy-related toxicity. Currently, nine antibody-drug conjugate-based formulations have been already approved and more than 80 are under clinical trials for the treatment of several tumors, especially breast cancer, lymphomas, and multiple myeloma. To date, no ADCs have been approved for the treatment of gynecological formulations, but many formulations have been developed and have reached the

SUBMITTER: Martin-Sabroso C 

PROVIDER: S-EPMC8541375 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature